Sialic acid-binding immunoglobulin-like lectin1 as a Novel Predictive Biomarker for Relapse in Graves' Disease -A multicenter study.

Related Articles

Sialic acid-binding immunoglobulin-like lectin1 as a Novel Predictive Biomarker for Relapse in Graves' Disease -A multicenter study.

Thyroid. 2017 Oct 17;:

Authors: Hashimoto K, Nishihara E, Matsumoto M, Matsumoto S, Nakajima Y, Tsujimoto K, Yamakage H, Asahara-Satoh N, Noh JY, Ito K, Miyauchi A, Mori M, Yamada M, Ogawa Y

Abstract
BACKGROUND: There are currently no reliable biomarkers to predict relapse in Graves' disease (GD). In the present study, we investigated novel diagnostic biomarkers to predict the long-term remission of or relapse in GD.
METHODS: A DNA microarray analysis was performed to examine gene expression in the peripheral leukocytes of a frequently relapsing patient with GD and a patient in long-term remission after the discontinuation of anti-thyroid drugs (ATDs). Based on the DNA microarray analysis, we focused on Sialic acid-binding immunoglobulin-like lectin1 (Siglec1) as a candidate novel biomarker to predict GD relapse. Three hundred and fifty-eight patients with GD in the thyroid clinics of four different hospitals in Japan were included in a cross-sectional study to establish whether Siglec1 mRNA levels distinguish GD relapse experience from long-term remission. An additional 55 patients with GD were enrolled in a prospective study to clarify whether Siglec1 mRNA levels at ATD discontinuation predict GD relapse.
RESULTS: Siglec1 mRNA levels were significantly higher in patients with GD relapse experience than in those in long-term remission. Based on the receiver operating characteristic (ROC) analysis, we found that high Siglec1 mRNA levels (≧258.9 copies) significantly distinguished GD relapse experience from long-term remission (P < 0.0001; sensitivity 66.7%, specificity 70.1%). In the prospective study, when the optimal cut-off value from the ROC curve analysis was applied to Siglec1 mRNA positivity at ATD discontinuation, Siglec1-positive patients (≧ 258.9 copies) showed a significantly higher cumulative risk of relapse than Siglec1-negative patients (< 258.9 copies) (P = 0.022, the Log-rank test).
CONCLUSIONS: Siglec1 mRNA levels have potential as a novel predictive biomarker for GD relapse.

PMID: 29037117 [PubMed - as supplied by publisher]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2gntKWk